Merck Revenue 2006-2018 | MRK

Merck annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

Merck revenue for the quarter ending December 31, 2018 was $10.998B, a 5.42% increase year-over-year.

Merck revenue for the twelve months ending December 31, 2018 was $42.294B, a 5.41% increase year-over-year.

Merck annual revenue for 2018 was $42.294B, a 5.41% increase from 2017.

Merck annual revenue for 2017 was $40.122B, a 0.79% increase from 2016.

Merck annual revenue for 2016 was $39.807B, a 0.78% increase from 2015.

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.